Share on StockTwits

Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been given a consensus rating of “Hold” by the eleven brokerages that are currently covering the stock, Analyst Ratings Net reports. Six analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is GBX 1,528.75 ($25.75).

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,500 ($25.27) to GBX 1,600 ($26.95) in a research note on Thursday. They now have a “hold” rating on the stock. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday. They now have a GBX 1,800 ($30.32) price target on the stock. Finally, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, May 7th. They now have a GBX 1,750 ($29.48) price target on the stock.

Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 0.75% on Friday, hitting GBX 1588.00. 65,020 shares of the company’s stock traded hands. Hikma Pharmaceuticals Plc has a 52-week low of GBX 903.50 and a 52-week high of GBX 1699.00. The stock’s 50-day moving average is GBX 1585. and its 200-day moving average is GBX 1364.. The company’s market cap is £3.140 billion.

Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.